Dogwood Therapeutics, Inc.
NASDAQ:DWTXBiotechnology
+$0.04 today
- Market cap
- $51.12M
- Beta
- 1.76
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.84
Volume 0.12M
Average 0.09M
Returns on capital
Dogwood Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-45.7%
avg -37.3%
ROIC
-32.1%
avg -21.9%
ROA
-38.0%
avg -555.9%
Analysis
ROIC is currently the strongest return metric at -32.1% versus its period average of -21.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Gregory Duncan | Chairman & Chief Executive Officer | USD 944.13K | 61 | — | — |
R. Michael Gendreau | Chief Medical Officer | USD 551.14K | 70 | — | — |
Angela Walsh | Chief Financial Officer, Secretary & Treasurer | USD 472.91K | 59 | 82.50K | 0.25% |
Ralph D. Grosswald | Senior Vice President of Operations | USD 274.69K | 57 | — | — |
William L. Pridgen | Founder & Member of Scientific Advisory Board | USD 16.33K | 65 | — | — |
Carol Duffy | Chief Scientific Advisor | — | — | — | — |
Compensation is shown in the reported currency; data updated Sep 12, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does Dogwood Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about DWTX's management, answered from reported figures.
Who manages DWTX?
Dogwood Therapeutics, Inc. (DWTX) lists 6 active executives. The top listed executive is R. Michael Gendreau, Chief Medical Officer.
Are DWTX insiders buying or selling?
Recent insider activity shows net buying of $7.75M.
Continue the stock analysis
Jump to another research area for this company.